---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-005863"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:03:43.269144+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MyMD Pharmaceuticals raises $15M via registered direct offering of Series F convertible preferred and warrants

## Summary
- 15,000 shares of Series F Convertible Preferred Stock, $1,000 stated value per share.
- Warrants to purchase up to 6,651,885 shares of common stock.
- Offering to accredited investors under Securities Purchase Agreement dated Feb 21, 2023.
- Legal opinions from DLA Piper and Haynes and Boone filed as exhibits.

## SEC filing metadata
- accession: 0001493152-23-005863
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005863/0001493152-23-005863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005863/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-005863
- JSON: https://secwatch.observer/filing/0001493152-23-005863.json
- Plain text: https://secwatch.observer/filing/0001493152-23-005863.txt

## Key facts
- Material Agreements
  Q/C TECHNOLOGIES, INC. entered into Securities Purchase Agreement with certain accredited investors valued at $1,000 per share (effective 2023-02-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $1,000 per share
  - Effective: 2023-02-21
  source text: As previously reported, on February 21, 2023, the Company entered into a definitive agreement (the “Securities Purchase Agreement”) with certain accredited investors to sell in a registered direct offering (i) an aggregate of 15,000 shares of the Company’s newly-designated Series F Convertible Preferred Stock with a stated value of $1,000 per share, convertible into shares of the Company’s common stock, no par value (the “Common Stock”), pursuant to the terms of the Securities Purchase Agreement, and (ii) warrants to acquire up to an aggregate of 6,651,885 shares of Common Stock, subject to adjustment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005863/0001493152-23-005863-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.